Henry Chi Hang Fung, MD, FRCPE
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111
Video: Henry Chi Hang Fung, MD, FRCPE
Director,Meet other members of the
Hematologic Oncology Treatment Team
Bone Marrow Transplant Program
Hematologic Oncology Treatment Team.
More information about the
Bone Marrow Transplant Program.
Multiple Myeloma, lymphoma, Blood and Marrow Transplantation
FRCPE, awarded by Royal College of Physician Edinburgh, 01/2001;
MRCP (UK), awarded by Royal College of Physicians, United Kingdom 10/1991
Cancer treatment and bone marrow transplant represent a journey for my patients and their families, and it’s my sincere privilege to be a part of this experience. I consider us all to be critical members of a cohesive team in making the right decisions to meet my patients’ treatment goals while maintaining quality of life.
MBChB Medicine, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, 1987
Hematology/Oncology, Queen Mary Hospital, Hong Kong University, 1991-1992;
Internal Medicine, Queen Mary Hospital, Hong Kong University, 1988-1991
Fellow, Hematology/Oncology, Queen Mary Hospital, Hong Kong University, Hong Kong;
Clinical Fellow, Division of Hematology, Vancouver Hospital and Health, Science Center, British Columbia Cancer Control Agency, University of British Columbia, Canada, 1992-1994
Honors and Awards
The Leading Physicians of the World, Top Oncologist in Chicago, International
Association of Oncologist, 2013;
Innovation Award (Henry C Fung MD and Rush SCT Program) – Chicago Chapter, American College of Health Executives, 2013;
Excellence Award, Chicago Chapter, Lymphoma Research Foundation, 2008;
Who’s Who in Medicine and Healthcare, 2007 – present;
Fellow, Royal College of Physicians Edinburgh, United Kingdom, 2001
American College of Physicians;
American Society of Hematology;
American Society of Clinical Oncology;
American Society of Blood and Marrow Transplantation;
Royal College of Physicians, Edinburgh, United Kingdom
Allogeneic Stem Cell Transplant using alternative donors; Treatment and Stem Cell Transplant for Multiple Myeloma, Lymphoma and Leukemias, Myelodysplasia, Myeloproliferative disease and Myelofibrosis.